 | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration |
Intramuscular, Intranasal |
| Legal status | |
| Legal status | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
 COVID-19 portal
|
Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute.
It's the second Iranian COVID-19 vaccine reaching human trials and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine. It received emergency use authorization in Iran on 31 October 2021.
Medical uses
It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).
Pharmacology
Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.
Manufacturing
It's planned to produce one million doses of the vaccine each month as of September 2021.
As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.
History
Clinical trials
| Phase | Registration number | Start | Number of participants | Age of participants | Ref | ||
|---|---|---|---|---|---|---|---|
| Total | Vaccine | Placebo | |||||
| I | IRCT20201214049709N1 | 21 January 2021 | 133 | 30 (5 µg/200µL)
30 (10 µg/200µL) 30 (20 µg/200µL) |
30 (placebo)
13 (sentinel) |
18-50 years | |
| II | IRCT20201214049709N2 | 13 April 2021 | 500 | 18-70 years | |||
| III | IRCT20201214049709N3 | 29 August 2021 | 41,128 | 20,564 | 0 (placebo)
20,564 (Sinopharm BIBP vaccine) |
18+ years | |
Authorizations
Raz Cov Pars received emergency use authorization in Iran on 31 October 2021.
